期刊
BLOOD
卷 122, 期 6, 页码 893-901出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2012-07-442012
关键词
-
类别
资金
- National Institutes of Health, National Cancer Institute [U54CA143798-01/CA/NCI NIH, 1R01CA138234-01/CA/NCI NIH, K08CA160647-01/CA/NCI NIH]
- Peter Solomon Fund at Memorial Sloan-Kettering Cancer Center
- MPN Research Foundation
- Starr Cancer Consortium
- American Society of Hematology
- National Natural Science Foundation of China [81170490]
- Leukemia and Lymphoma Society
Pegylated interferon alpha-2a (PEG-IFN-alpha-2a) has previously been shown to induce hematologic and molecular responses in patients with polycythemia vera (PV) or essential thrombocythemia (ET). Here we present a follow-up of a phase 2 trial with PEG-IFN-alpha-2a treatment in 43 PV and 40 ET patients with detailed molecular analysis. After a median follow-up of 42 months, complete hematologic response was achieved in 76% of patients with PV and 77% of those with ET. This was accompanied by complete molecular response (CMR) (ie, undetectable JAK2V617F) in 18% and 17%, of PV and ET patients, respectively. Serial sequencing of TET2, ASXL1, EZH2, DNMT3A, and IDH1/2 revealed that patients failing to achieve CMR had a higher frequency of mutations outside the Janus kinase-signal transducer and activator of transcription pathway and were more likely to acquire new mutations during therapy. Patients with both JAK2V617F and TET2 mutations at therapy onset had a higher JAK2V617F mutant allele burden and a less significant reduction in JAK2V617F allele burden compared with JAK2 mutant/TET2 wildtype patients. These data demonstrate that PEG-IFN-alpha-2a induces sustained CMR in a subset of PV or ET patients, and that genotypic context may influence clinical and molecular response to PEG-IFN-alpha-2a.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据